Cost-Utility Analysis of Add-on Cannabidiol vs Usual Care Alone for the Treatment of Seizures in Patients With Treatment-Resistant Lennox-Gastaut Syndrome or Dravet Syndrome in the Netherlands
**Background:** Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) are severe, treatment-refractory, epileptic encephalopathies that often develop in infancy or early childhood. Since December 1, 2022, plant-derived highly purified cannabidiol (CBD) medicine (Epidyolex®; 100 mg/mL oral solution)...
Saved in:
Main Authors: | Jamshaed Siddiqui, Sally Bowditch |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2024-12-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/001c.126071 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of cohort definitions and algorithms to identify patients with Lennox-Gastaut syndrome or Dravet syndrome from real-world administrative healthcare databases
by: Drishti Shah, et al.
Published: (2025-02-01) -
Refining management strategies for Lennox–Gastaut syndrome: Updated algorithms and practical approaches
by: Stéphane Auvin, et al.
Published: (2025-02-01) -
The Effectiveness of Add-on Treatment with Nutraceutical
by: V. T. Ivashkin, et al.
Published: (2022-08-01) -
Dravet Syndrome in Lebanon: First Report on Cases with SCN1A Mutations
by: Saada Alame, et al.
Published: (2019-01-01) -
Use of Stiripentol in Patients with Dravet Syndrome: Common Practice Among Experts in Spain
by: Juan José García-Peñas, et al.
Published: (2024-11-01)